Cambridge, MA/Toronto CA – June 2, 2025 – Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D with its AI foundation model platform, have added two highly respected scientific leaders to its Scientific Advisory Board: Vic Myer, PhD, as Chair, and Richard Scheller, PhD.
"Having Vic and Richard on our Advisory Board marks a pivotal moment for Deep Genomics," said Greg Hoffman, Chief Scientific Officer of Deep Genomics. "Their collective expertise in advancing innovative medicines through both biotechnology and data-driven approaches are essential as we continue building a future where AI and biology seamlessly converge to transform drug discovery.”
Vic Myer brings three decades of interdisciplinary experience to the Advisory Board, where he will help guide the company in applying its AI platform to the most critical problems in genetic medicine. He is currently an Advisory Board member for multiple genomic medicine and delivery technology organizations, as well as an advisor for Atlas Ventures and the NIH Somatic Cell Genome Engineering Initiative. His prior operational leadership includes serving as President and Chief Scientific Officer at Chroma Medicine and Chief Technology Officer at Editas Medicine.
Myer commented, "I'm excited and honored to be joining Deep Genomics as Chair of the Scientific Advisory Board. This is an opportunity to work with a world class group of advisors with deep experience in AI & drug development, as well as the very talented scientists on Deep Genomics’ R&D team. I look forward to the Advisory Board serving as a key resource to advance their mission to be the industry leader in applying Artificial Intelligence for RNA Biology to develop important genetic medicines."
Richard Scheller, PhD, is an award-winning leader in drug discovery and therapeutic development. He previously served as Head of Therapeutics and Chief Scientific Officer at 23andMe and as Executive Vice President of Research and Early Development at Genentech, where he led major initiatives in research strategy and early drug development. Earlier in his career, he was a professor at Stanford and a Howard Hughes Medical Institute investigator, and he currently holds an adjunct faculty position at the University of California, San Francisco. Scheller currently sits on the boards of several respected biotech organizations.
“It’s a privilege to deepen my longstanding collaboration with Deep Genomics as a member of the Scientific Advisory Board,” said Scheller. “The convergence of AI and biology is redefining what’s possible in drug discovery, and Deep Genomics sits at the helm of that transformation. I am honored for the opportunity to help guide work that is reshaping the landscape of therapeutics.”
To learn more about Deep Genomics’ work and its groundbreaking impact in the realm of genomic R&D, visit www.deepgenomics.com. For those interested in joining this team of TechBio innovators, visit https://www.deepgenomics.com/careers/.
About Deep Genomics
Deep Genomics is a multidisciplinary team of AI and biology scientists dedicated to pioneering a new era of genomic research and development through its AI foundation models platform. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-saving therapeutics to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on LinkedIn and Twitter.
Media Contact
Mandy Mellinger
Fight or Flight
deepgenomics@fightorflight.com